A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia-Reference-Cited by-同舟云学术

A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia

Published:2023-05-30 Issue:6 Volume:43 Page:401-411
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Ding Ruilin,Chen Longxia,Li Xinghai,Xiong Tengqiong,Chen Hong,Hu Xiaojing,Li Yun,Zhou Yi,Liu Kezhi,Wu Jianhong,Jiang Feng,Peng Qing^ORCID

Funder

Hinova Pharmaceuticals Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-023-01274-7.pdf

Reference24 articles.

1. Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperursicaemia: a randomized controlled phase II study. Rheumatology. 2021;60:5089–97. https://doi.org/10.1093/rheumatology/keab198.

2. Hosoya T, Furuno K, Kanda S. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients. Clin Exp Nephrol. 2020;24:103–11. https://doi.org/10.1007/s10157-020-01857-0.

3. Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. Clin Exp Nephrol. 2017;21:182–92. https://doi.org/10.1007/s10157-016-1288-2.

4. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12:3167–81.

5. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380–90. https://doi.org/10.1038/s41584-020-0441-1.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia;Scientific Reports;2023-12-14